Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728

Thromb Res. 1997 Oct 15;88(2):137-46. doi: 10.1016/s0049-3848(97)00225-9.

Abstract

The effects of alpha IIb beta 3 antagonists on the blockade of fibrinogen binding to platelet alpha IIb beta 3 are well documented, however, little is known about their effects on platelet secretion. We compare here the effect of two potent alpha IIb beta 3 antagonists, c7E3 and DMP728, on platelet secretion. Using human platelet-rich plasma, P-selectin expression was measured by flow cytometry and type 1 plasminogen activator inhibitor (PAI-1) secretion as well as beta-thromboglobulin (beta-TG) were determined by ELISA. At various concentrations of the antagonists that inhibited 80-95% of platelet aggregation, neither had any effect on P-selectin expression. In contrast, thrombin-stimulated PAI-1 secretion is only inhibited by c7E3, 49.6% at 3.5 mumol/L (p < 0.05), but not at any other maximally effective anti-aggregatory concentrations of c7E3 or DMP728. Furthermore, a lack of any significant effects on platelet granular secretion of beta-TG induced by either thrombin or ADP was demonstrated with DMP728, c7E3 or LM609. Two protein kinase inhibitors, staurosporine and herbimycin, blocked both ADP and thrombin-induced P-selectin expression at 10 mumol/L, but not PAI-1 secretion. Taken together this suggests that: (1) the mechanism of platelet granular secretion is independent of the integrin alpha IIb beta 3 and (2) the subcellular locations of PAI-1, beta-TG and P-selectin or the signaling mechanisms that regulate their secretion might be different. Although there is no direct effect of platelet alpha IIb beta 3 antagonists on platelet secretion of PAI-1, beta-TG and P-selectin, the present data demonstrates that reduction of platelet number by alpha IIb beta 3 antagonists, via the reduction in thrombus size, might be an alternate mechanism for reduced platelet secretion. In conclusion, a discoupling between the anti-aggregatory and the anti-secretory effects of alpha IIb beta 3 antagonists has been demonstrated.

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / pharmacology*
  • Benzoquinones
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Immunoglobulin Fab Fragments / pharmacology*
  • Lactams, Macrocyclic
  • Mesylates / pharmacology*
  • Oligopeptides / pharmacology*
  • P-Selectin / biosynthesis
  • P-Selectin / blood
  • P-Selectin / drug effects
  • Peptides, Cyclic / pharmacology*
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
  • Quinones / pharmacology
  • Rifabutin / analogs & derivatives
  • Staurosporine / pharmacology
  • beta-Thromboglobulin / analysis
  • beta-Thromboglobulin / metabolism

Substances

  • Antibodies, Monoclonal
  • Benzoquinones
  • Enzyme Inhibitors
  • Immunoglobulin Fab Fragments
  • Lactams, Macrocyclic
  • Mesylates
  • Oligopeptides
  • P-Selectin
  • Peptides, Cyclic
  • Plasminogen Activator Inhibitor 1
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Quinones
  • beta-Thromboglobulin
  • DMP 728
  • Rifabutin
  • herbimycin
  • arginyl-glycyl-aspartic acid
  • Staurosporine
  • Abciximab